Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Accumulated Expenses (2016 - 2026)

Champions Oncology has reported Accumulated Expenses over the past 16 years, most recently at $3.3 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $3.3 million for Q1 2026, up 47.6% from a year ago — trailing twelve months through Jan 2026 was $3.3 million (up 47.6% YoY), and the annual figure for FY2025 was $2.6 million, up 18.33%.
  • Accumulated Expenses for Q1 2026 was $3.3 million at Champions Oncology, up from $2.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CSBR hit a ceiling of $3.3 million in Q1 2026 and a floor of $1.7 million in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $2.2 million (2024), compared with a mean of $2.2 million.
  • Biggest five-year swings in Accumulated Expenses: decreased 14.12% in 2025 and later surged 47.6% in 2026.
  • Champions Oncology's Accumulated Expenses stood at $1.7 million in 2022, then increased by 21.14% to $2.0 million in 2023, then rose by 10.48% to $2.2 million in 2024, then dropped by 2.1% to $2.2 million in 2025, then soared by 52.93% to $3.3 million in 2026.
  • The last three reported values for Accumulated Expenses were $3.3 million (Q1 2026), $2.2 million (Q4 2025), and $1.8 million (Q3 2025) per Business Quant data.